Blueprint Medicines Corporation
BPMC
$101.50
$1.161.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.08% | 14.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.08% | 14.18% | |||
| Cost of Revenue | -62.37% | 285.46% | |||
| Gross Profit | 5.54% | 10.03% | |||
| SG&A Expenses | -0.67% | 7.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.56% | 5.88% | |||
| Operating Income | 0.28% | 15.87% | |||
| Income Before Tax | 102.61% | 12.00% | |||
| Income Tax Expenses | 17.41% | 146.15% | |||
| Earnings from Continuing Operations | 100.99% | 11.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.99% | 11.23% | |||
| EBIT | 0.28% | 15.87% | |||
| EBITDA | 1.55% | 17.53% | |||
| EPS Basic | 100.98% | 11.53% | |||
| Normalized Basic EPS | 33.41% | -29.28% | |||
| EPS Diluted | 100.98% | 11.53% | |||
| Normalized Diluted EPS | 35.85% | -29.28% | |||
| Average Basic Shares Outstanding | 0.78% | 0.35% | |||
| Average Diluted Shares Outstanding | 4.60% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||